# Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension

> **NCT01479010** · PHASE1,PHASE2 · TERMINATED · sponsor: **Virginia Commonwealth University** · enrollment: 2 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Anakinra 100 mg subcutaneously daily

## Key facts

- **NCT ID:** NCT01479010
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** recruitment issues, critical investigators left institution
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01479010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01479010, "Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01479010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*